Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

(CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 cents per share. Losses, adjusted for one-time gains and ...

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

Robert W. Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock ...

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...